GO:0030297 transmembrane receptor protein tyrosine kinase activator activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030297 describes a molecular function in which a protein binds to and increases the catalytic activity of a transmembrane receptor protein tyrosine kinase.
• Classic examples include ligand-induced activation of the insulin receptor and KIT by their cognate growth factors, where activator binding stabilizes the active kinase conformation.
• Activator proteins can act as secreted ligands, membrane-anchored co-receptors, or intracellular scaffolds that promote receptor dimerization and trans-autophosphorylation.
• Dysregulated activator activity contributes to cancer, metabolic disease, and tissue atrophy through aberrant RTK signaling.
• CRISPR knockout, point-mutation knock-in, and overexpression models are essential to dissect whether a candidate activator is causally required for RTK signaling.
• EDITGENE provides end-to-end CRISPR cell model generation and library screening to study GO:0030297-related genes at scale.
Description
Transmembrane receptor protein tyrosine kinases (RTKs) are cell-surface receptors that convert extracellular cues into intracellular phosphorylation signals. Their activity is not intrinsic alone; it depends on activator proteins that bind and enhance receptor kinase function, a molecular function captured by GO:0030297. This term is defined as binding to and increasing the activity of a transmembrane receptor protein tyrosine kinase, and it is central to understanding how growth factors, hormones, and cytokines initiate signaling. Classic examples include insulin binding to the insulin receptor, which stimulates receptor tyrosine kinase activity and downstream metabolic responses. Similarly, stem cell factor activates KIT through direct binding and receptor dimerization. Because RTK activation is a rate-limiting step in many signaling cascades, proteins annotated with GO:0030297 are high-value targets for mechanistic and therapeutic research.
transmembrane receptor protein tyrosine kinase activator activity At A Glance
| GO ID | GO:0030297 |
|---|---|
| GO term | transmembrane receptor protein tyrosine kinase activator activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binds to and increases the activity of a transmembrane receptor protein tyrosine kinase |
| Example activators | Insulin (activates INSR), stem cell factor (activates KIT), and other RTK ligands or co-receptors |
| Cellular context | Cell surface, extracellular space, and membrane-proximal signaling complexes |
| Related processes | RTK signaling, cell proliferation, differentiation, metabolism, and survival |
What Is GO:0030297?
GO:0030297 (transmembrane receptor protein tyrosine kinase activator activity) is a molecular function term describing any protein that binds to a transmembrane receptor protein tyrosine kinase and increases its enzymatic activity. This activation typically involves promoting receptor dimerization, stabilizing the active kinase conformation, or facilitating trans-autophosphorylation, leading to enhanced downstream signaling.
Why Is transmembrane receptor protein tyrosine kinase activator activity Important in Cell Biology?
GO:0030297 is important because it defines the molecular trigger for RTK signaling, a process that controls cell growth, metabolism, differentiation, and survival. Dysregulation of activator proteins or their receptors underlies many human diseases, including cancer, diabetes, and tissue degeneration. Understanding which proteins act as activators and how they engage RTKs is therefore critical for drug discovery and for interpreting disease-associated mutations.
• RTK activator activity is the first step in many growth factor signaling pathways.
• Insulin receptor activation by insulin is a prototype for metabolic regulation.
• KIT activation by stem cell factor controls hematopoiesis and pigmentation.
• Aberrant RTK activation drives multiple cancers through mutations or autocrine loops.
• Activator proteins can be secreted, membrane-bound, or intracellular, adding regulatory complexity.
• Exercise-induced factors such as Nrg4 can modulate systemic metabolism via RTK-related pathways.
• IGF-1/IGF-1R activation is linked to skeletal muscle atrophy and hypertrophy.
• BDNF expression, influenced by exercise and ketone bodies, intersects with RTK signaling in the brain.
• Targeting activator-receptor interfaces is a therapeutic strategy in oncology.
• CRISPR screens can identify novel GO:0030297 genes in a unbiased manner.
Molecular Mechanism of transmembrane receptor protein tyrosine kinase activator activity
Ligand binding and receptor engagement
In simple terms: An activator protein grabs onto the outside of a receptor, like a key fitting a lock.
The activator, often a secreted ligand such as insulin or stem cell factor, binds to the extracellular domain of its cognate RTK. This binding is specific and high-affinity, and it induces conformational changes in the receptor that are required for activation.
Receptor dimerization and trans-autophosphorylation
In simple terms: Two receptors come together and switch each other on by adding phosphate tags.
Upon activator binding, RTK monomers dimerize or undergo conformational rearrangement, allowing the intracellular kinase domains to phosphorylate each other on tyrosine residues. This trans-autophosphorylation creates docking sites for downstream signaling proteins.
Stabilization of the active kinase conformation
In simple terms: The activator keeps the receptor in its 'on' shape.
Some activators function by stabilizing the active conformation of the RTK kinase domain, preventing it from returning to an autoinhibited state. This can involve allosteric interactions or co-receptor assembly.
Downstream signal initiation
In simple terms: The activated receptor sends a message into the cell.
Phosphorylated RTKs recruit adaptor proteins and enzymes such as PI3K and GRB2, leading to activation of pathways like PI3K/Akt and MAPK. These pathways control gene expression, metabolism, and cell fate.
Regulation and feedback
In simple terms: The cell has brakes to stop the signal.
Activator-driven RTK signaling is tightly regulated by phosphatases, endocytosis, and negative feedback loops. Dysregulation of these brakes can lead to sustained activation and disease.
Key Genes Involved in GO:0030297 transmembrane receptor protein tyrosine kinase activator activity
The following genes encode proteins that either act as activators (GO:0030297) or are the transmembrane receptor tyrosine kinases they activate, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| INS | Secreted activator of INSR | Metabolic regulation, diabetes research |
| INSR | Transmembrane RTK activated by insulin | Insulin signaling, glucose uptake |
| KITLG | Stem cell factor, activator of KIT | Hematopoiesis, pigmentation, cancer |
| KIT | RTK activated by KITLG | Gastrointestinal stromal tumors, mastocytosis |
| IGF1 | Activator of IGF1R | Muscle atrophy, growth |
| IGF1R | RTK activated by IGF1 | Muscle hypertrophy, cancer |
| NRG4 | Adipokine activator of ERBB4 | Metabolic liver disease |
| ERBB4 | RTK activated by NRG4 | MASLD, neuronal signaling |
| BDNF | Neurotrophin activator of NTRK2 | Neuroplasticity, exercise response |
| NTRK2 | RTK activated by BDNF | Depression, memory |
| MST1R | RON RTK, activated by MSP | Cancer, inflammation |
| MST1 | Activator of MST1R | Macrophage activation |
| HGF | Activator of MET | Liver regeneration, cancer |
| MET | RTK activated by HGF | Oncogenesis, metastasis |
| EGF | Activator of EGFR | Proliferation, cancer |
| EGFR | RTK activated by EGF | Lung cancer, targeted therapy |
| VEGFA | Activator of KDR | Angiogenesis, cancer |
How Is transmembrane receptor protein tyrosine kinase activator activity Regulated?
GO:0030297 activity is regulated at multiple levels. Activator expression can be controlled transcriptionally or by secretion. Receptor availability is modulated by endocytosis and recycling. Negative feedback via phosphatases such as PTP1B and SOCS proteins dampens RTK signaling. Additionally, exercise-induced factors like β-hydroxybutyrate can influence BDNF expression, indirectly affecting RTK activator levels. Metabolic states, including those altered by exercise, can modulate IGF-1/IGF-1R signaling.
transmembrane receptor protein tyrosine kinase activator activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KIT | Gastrointestinal stromal tumor | Knock-in of KIT mutations in cell lines |
| INSR | Type 2 diabetes | Knockout of INSR in hepatocytes |
| IGF1 | Skeletal muscle atrophy | Overexpression of IGF1 in myotubes |
| NRG4 | MASLD | Knockout of NRG4 in mouse liver |
| BDNF | Depression, neuroplasticity | Knock-in of BDNF variants in neurons |
Cancer
Many cancers harbor mutations that constitutively activate RTKs or overexpress their activators, leading to uncontrolled proliferation. For example, KIT mutations in gastrointestinal stromal tumors mimic stem cell factor activation. Similarly, MET amplification or HGF overexpression drives tumor growth.
Metabolic disorders
Insulin resistance in type 2 diabetes involves impaired insulin receptor activation and downstream signaling. Activator proteins like Nrg4 can alleviate metabolic dysfunction by modulating RTK pathways.
Muscle atrophy
IGF-1/IGF-1R signaling is a key regulator of muscle mass. Reduced IGF-1 activator activity contributes to skeletal muscle atrophy in conditions like myocardial infarction.
Neurodegeneration and neuroplasticity
BDNF, an activator of NTRK2, is critical for neuronal survival and plasticity. Exercise-induced BDNF expression via β-hydroxybutyrate highlights the link between metabolism and RTK activator function.
From transmembrane receptor protein tyrosine kinase activator activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is the activator required for RTK signaling? | CRISPR knockout of the activator gene |
| Does a point mutation alter activator binding? | Point-mutation knock-in of the activator |
| Can a tagged activator be tracked in live cells? | Tagged knock-in (e.g., GFP) of the activator |
| Does overexpression drive oncogenic transformation? | Overexpression of the activator in cell lines |
| Which genes regulate RTK activation? | CRISPR library screening |
| What is the transcriptional response to activator loss? | RNA-seq after knockout |
How to Study the transmembrane receptor protein tyrosine kinase activator activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function phenotype | Identify essential activators |
| Point mutation knock-in | Effect of specific amino acid changes | Dissect binding interfaces |
| Tagged knock-in | Protein localization and dynamics | Live-cell imaging |
| Overexpression | Gain-of-function phenotype | Test oncogenic potential |
| Phosphoproteomics | Phosphorylation changes | Measure RTK activity |
| RNA-seq | Transcriptional changes | Identify downstream pathways |
| CRISPR library screening | Fitness or reporter changes | Discover novel regulators |
CRISPR knockout screens
Genome-wide knockout screens can identify genes whose loss alters RTK activation or downstream signaling. This is useful for discovering novel GO:0030297 activators.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics measures changes in RTK phosphorylation upon activator manipulation, providing direct readout of kinase activity.
Live-cell imaging
Fluorescently tagged activators and receptors can be imaged to track binding, dimerization, and internalization in real time.
Transcriptomics
RNA-seq after activator knockout or overexpression reveals downstream gene expression changes and feedback mechanisms.
How CRISPR Can Be Used to Study GO:0030297 transmembrane receptor protein tyrosine kinase activator activity
Knockout
CRISPR knockout of a candidate activator gene abolishes its function, allowing researchers to test whether it is required for RTK activation and downstream signaling. This is often the first step in validating GO:0030297 annotations.
Point Mutation
Point-mutation knock-in introduces specific amino acid substitutions to disrupt or enhance activator-receptor binding. This helps map the exact residues critical for GO:0030297 activity.
Knock-in
Tagged knock-in (e.g., GFP or HA) enables visualization and immunoprecipitation of the activator in its native genomic context, facilitating interaction studies.
Overexpression
Overexpression of an activator can mimic disease states such as cancer, where excess activator drives constitutive RTK signaling. This is useful for gain-of-function studies.
How EDITGENE Supports transmembrane receptor protein tyrosine kinase activator activity Research
Researchers studying transmembrane receptor protein tyrosine kinase activator activity-related genes often need to determine whether a candidate gene is causally involved in RTK signaling or is merely correlated. EDITGENE provides the CRISPR tools and cell models to establish causality with precision.
Contact EDITGENE today to design your custom CRISPR model for transmembrane receptor protein tyrosine kinase activator activity research.
Frequently Asked Questions About transmembrane receptor protein tyrosine kinase activator activity
What is transmembrane receptor protein tyrosine kinase activator activity?
It is a molecular function (GO:0030297) where a protein binds to and increases the activity of a transmembrane receptor protein tyrosine kinase.
What genes are involved in transmembrane receptor protein tyrosine kinase activator activity?
Genes include INS, KITLG, IGF1, NRG4, BDNF, HGF, EGF, and VEGFA, which encode activators of receptors like INSR, KIT, IGF1R, ERBB4, NTRK2, MET, EGFR, and KDR.
How does an activator increase receptor tyrosine kinase activity?
It typically promotes receptor dimerization and trans-autophosphorylation, stabilizing the active kinase conformation.
What diseases are linked to RTK activator dysfunction?
Cancers, diabetes, muscle atrophy, and neuropsychiatric disorders can involve dysregulated RTK activation.
What is the difference between a ligand and an activator?
Many ligands are activators, but activators can also be membrane-bound or intracellular proteins that enhance RTK activity without being the primary ligand.
How can I study GO:0030297 in the lab?
Use CRISPR knockout, point-mutation knock-in, overexpression, and phosphoproteomics to measure RTK activity.
What cell models are best for studying RTK activators?
The choice depends on the receptor; for example, hepatocytes for INSR, melanocytes for KIT, and neurons for NTRK2.
Can CRISPR screens identify new RTK activators?
Yes, genome-wide knockout or activation screens can uncover novel regulators of RTK signaling.
What is the role of KIT in RTK activator activity?
KIT is a receptor tyrosine kinase activated by stem cell factor (KITLG), a classic example of GO:0030297.
How does exercise relate to RTK activator activity?
Exercise can modulate IGF-1 and BDNF, which are activators of IGF1R and NTRK2, respectively.
Conclusion
GO:0030297 defines a critical molecular function that controls RTK signaling, with broad implications for cancer, metabolism, and neuroscience. Understanding the activators and their mechanisms provides opportunities for therapeutic intervention. EDITGENE offers comprehensive CRISPR solutions to study these activators in any cell model.
References
- 1. Feng L et al.. 2022. Aerobic exercise and resistance exercise alleviate skeletal muscle atrophy through IGF-1/IGF-1R-PI3K/Akt pathway in mice with myocardial infarction.. Am J Physiol Cell Physiol 322(2):C164-C176 PMID: 34852207
- 2. Chen M et al.. 2025. Exercise-induced adipokine Nrg4 alleviates MASLD by disrupting hepatic cGAS-STING signaling.. Cell Rep 44(2):115251 PMID: 39891907
- 3. Trenker R et al.. 2020. Receptor tyrosine kinase activation: From the ligand perspective.. Curr Opin Cell Biol 63:174-185 PMID: 32114309
- 4. Gammeltoft S et al.. 1986. Protein kinase activity of the insulin receptor.. Biochem J 235(1):1-11 PMID: 3017297
- 5. Sleiman SF et al.. 2016. Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate.. Elife 5 PMID: 27253067
- 6. Roskoski R Jr. 2005. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.. Biochem Biophys Res Commun 338(3):1307-15 PMID: 16226710
- 7. Ballotti R et al.. 1989. Insulin receptor: tyrosine kinase activity and insulin action.. Reprod Nutr Dev 29(6):653-61 PMID: 2534271
- 8. Danilkovitch-Miagkova A et al.. 2001. Cross-talk between RON receptor tyrosine kinase and other transmembrane receptors.. Histol Histopathol 16(2):623-31 PMID: 11332718
